30 results about "Dominant-Negative Mutant" patented technology

Disclosed are mutant CDK inhibitor (CKI) polypeptides having dominant negative antagonist activity against wild-type CKI proteins, as well as related compositions, including nucleic acids and vectors encoding the mutant CKI polypeptides and transformed host cells and transgenic plants comprising such nucleic acids and vectors. Also disclosed are related methods for using the mutant proteins to modulate cell division in cells, particularly plant cells.

The present invention provides a method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells, comprising inhibiting the p53 function in the step of somatic cell nuclear reprogramming. The inhibition of p53 function is achieved by bringing a substance selected from the group consisting of (1) chemical inhibitors of p53, (2) dominant negative mutants of p53 and nucleic acids that encode the same, (3) siRNAs and shRNAs against p53 and DNAs that encode the same, and (4) p53 pathway inhibitors, into contact with a somatic cell, and the like. The present invention also provides an agent for improving the efficiency of establishment of iPS cells, the agent comprising an inhibitor of p53 function, particularly (1) chemical inhibitors of p53, (2) dominant negative mutants of p53 and nucleic acids that encode the same, (3) siRNAs and shRNAs against p53 and DNAs that encode the same, and (4) p53 pathway inhibitors. The present invention further provides a method of producing an iPS cell, comprising bringing a nuclear reprogramming substance and an inhibitor of p53 function into contact with a somatic cell.

The invention provides mutant forms of pore-forming toxins. These mutant toxins may be used in vaccines for the prevention of bacterial infection. Additionally, dominant negative mutants may be administered as therapeutics for the treatment of bacterial infection.

Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.

An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells.

A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.

The invention relates to plants and plant cells which have a transient or permanent virus resistance as a result of modulation of the gene expression and/or binding behavior of vegetable DnaJ-like proteins. The invention also relates to methods for the production of transgenic plants with increased virus resistance, wherein the expression of vegetable DnaJ-like proteins which interact with viral components is substantially prevented by silencing the DnaJ-like proteins. The invention further relates to methods for the production of transgenic plants with increased virus resistance, wherein the interaction of viral components with vegetable DnaJ-like proteins is substantially prevented by expression of dominant-negative mutants of the DnaJ-like proteins, by antibodies against DnaJ-like proteins or by specific inhibitors.

The present invention provides a genetically modified plant that biosynthesizes an increased amount of capsinoids, a method of producing the genetically modified plant, and a production method of capsinoids from the genetically modified plant. More particularly, the present invention provides a genetically modified plant capable of producing capsinoids, which shows a decreased expression or activity of an enzyme that catalyzes an amino group conversion reaction from vanillin to vanillylamine as compared to wild strains, and the like. As a method of suppressing expression or activity of an enzyme, an introduction of DNA encoding an antisense RNA, iRNA, ribozyme or dominant-negative mutant for the target gene, a destruction of the gene by a knockout method, mutagen treatment or transposon insertion, an introduction of a gene encoding an antibody against the enzyme and the like can be mentioned.

The present invention provides a method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells by inhibiting p38 function in the step of somatic cell nuclear reprogramming. The p38 function can be inhibited by bringing an inhibitor selected from the group consisting of (1) a chemical inhibitor of p38 (2) a dominant negative mutant of p38 or a nucleic acid that encodes the same, (3) a nucleic acid selected from the group consisting of siRNAs and shRNAs targeted to p38 and DNAs that encode the same and (4) an inhibitor of p38 pathway into contact with a somatic cell and the like. The present invention also provides an agent for improving the efficiency of establishment of induced pluripotent stem cells, which contains an inhibitor of p38 function, particularly an inhibitor selected from the group consisting of (1) a chemical inhibitor of p38 (2) a dominant negative mutant of p38 or a nucleic acid that encodes the same, (3) a nucleic acid selected from the group consisting of siRNAs and shRNAs targeted to p38 and DNAs that encode the same and (4) an inhibitor of p38 pathway. Moreover, the present invention provides a production method of iPS cells, which includes bringing a nuclear reprogramming substance and an inhibitor of p38 function into contact with a somatic cell.

The present invention provides dominant negative mutants of FGF2 for suppressing FGF-mediated cellular signaling. Related compositions, methods, and kits are disclosed.

The present invention provides an animal model for Parkinson's Disease and a method for generating such a model. The method comprises the steps of transfecting dopaminergic neurons in the substantia nigra with a dominant negative mutant of FGFR1 with deleted tyrosine kinase domain. The animals are characterized by a reduction in the number of tyrosine hydroxylase neurons in the SNc area.

The invention relates to the technical field of animal bacteriology and anthropozoonosis science, in particular to the application of dominant negative mutant F427N as bacillus anthracis toxin inhibitor and vaccine. In the invention, by the methods of bacillus anthracis lethal toxin gene clone, protein expression and purification, gene fixed point saturation mutation and the like, the protective antigen protein of the bacillus anthracis (namely, dominant negative mutant F427N) is obtained. The mutant is successfully cloned to bacterial expression vector pGEX-KG, thus forming recombinant plasmid pGEX-KG-PA (F427N). The colon bacillus containing the recombinant plasmid is named as Escherichia coli DH5 alpha/pGEX-KG-PA (F427N) and preserved at China Center for Type Culture Collection. The preservation code is CCTCC-M208159. The invention also discloses a method for preparing the antigen protein, a method for preparing the anthrax toxin inhibitor and subunit vaccine with the antigen protein and the application thereof.